Weight loss weightloss weight loss programs weight loss foods weight loss tips
| Source: Obalon Therapeutics, Inc.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.
Financial results for the first quarter of 2020
Revenue for the first quarter of 2020 was $0.8 million, compared to $1.8 million for the first quarter of 2019. Net loss for the first quarter of 2020 was $5.3 million, compared to $8.3 million for the first quarter of 2019. Net loss per share for the first quarter of 2020 was $0.68, compared to $3.59 for the first quarter of 2019.
Cost of revenue was $0.5 million for the first quarter of 2020, down from $1.2 million for the first quarter of 2019. Gross profit for the first quarter of 2020 was $0.2 million, down from $0.5 million for the first quarter of 2019.
Research and development expense for the first quarter of 2020 totaled $1.3 million, down from $2.4 million for the first quarter of 2019. Selling, general and administrative expense decreased to $3.9 million for the first quarter of 2020, compared to $6.2 million for the first quarter of 2019.
Operating loss for the first quarter of 2020 was $4.9 million, down from a loss of $8.1 million for the first quarter of 2020.
In the first quarter ended March 31, 2020, the Company did not record any asset impairment charges, but it would expect to record certain long-lived asset and inventory impairment charges in the second quarter ended June 30, 2020 related to its decision to move away from the retail treatment center model. The Company estimates the second quarter impairment charge to be in a range between $0.8 million and $1.4 million.
As of March 31, 2020, the Company had cash and cash equivalents of $8.9 million and no debt. The Company believes its cash and cash equivalents as of March 31, 2020 are sufficient to fund its operations only through the end of 2020. If the Company is not able to raise additional capital to meet its needs, it will not be able to support any ongoing operations and may not be able to settle all of its liabilities. The Company has actively reviewed financial and strategic alternatives, including debt and equity financing, whole or partial sale of the company and a reverse merger in order to meet its capital needs and financial obligations, and to date it has been unable to identify a viable alternative for capital raising.
On June 16, 2020, the Company and certain of its executive officers reached a settlement with the plaintiffs in its ongoing securities class action litigation, and they intend to submit a final settlement agreement for court approval. The settlement provides that the defendants continue to deny the allegations and claims asserted by the plaintiffs, and are entering into the settlement solely to eliminate the burden and expense of further litigation. The Company expects that any amounts due as part of the settlement will be covered by the Company’s insurance policies.
In March 2020, the Company announced that the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California as a result of COVID-19 had a significant impact on its business. As a result, the Company halted sales to new patients in its company-branded retail treatment centers, terminated expansion plans for additional retail centers and subsequently closed the two retail treatment centers it had opened. The Company also halted manufacturing operations and has not filled orders to U.S. customers or its former international distributor since that time.
Given those impacts and the significant concern about an economic recovery that would allow consumers to feel confident enough to spend on a cash-pay procedure like the Obalon Balloon System, the Company does not currently plan to re-open its retail treatment centers, re-initiate its retail treatment center expansion plans, or plan to ship orders to U.S. customers or its former international distributor. As a result, the Company would not expect to report any meaningful revenue for the foreseeable future.
The Company continues to believe the Obalon Balloon System can provide significant benefits to patients and value to the healthcare system. However, treatment with the Obalon Balloon System is not currently covered by any kind of private or public health insurance. The Company believes this has contributed to slow commercial adoption of the product and the procedure, as physicians are not reimbursed for treating patients with the Obalon therapy and patients must pay solely out of pocket for the Obalon Balloon System and the procedure. With that in mind, the Company is initiating efforts to explore obtaining third-party payor reimbursement and coverage for the Obalon Balloon System. The Company believes that reimbursement and coverage for the Obalon Balloon System could significantly expand its market opportunity. There are more than 70 million adults in the United States who are obese and over 11 million adults in the United States who have Type 2 diabetes and are obese. Moreover, the COVID-19 pandemic has further highlighted the personal health and economics costs of the obesity epidemic in the United States. Recently published data suggest that next to age, the underlying health conditions of obesity and obesity-related health conditions (hypertension and diabetes) are the greatest predictors of COVID-19 hospitalizations and death. The Company believes the Obalon Balloon System could help reduce third-party payors’ costs and improve patient care, and the Company intends to explore how additional data may be collected to demonstrate the economic and clinical evidence necessary to secure reimbursement. However, obtaining reimbursement is never certain and can take many years to achieve, and if achieved, may not be determinative of the Company’s success. If the Company’s initial efforts with payors begin to bear success, it would expect to need to raise additional capital to support those efforts.
To enable it to pursue this reimbursement strategy, the Company is taking further steps to significantly reduce expenses in an effort to extend its cash runway. The Company has significantly reduced the organization to only essential personnel and expects that, after a transition, only two full-time employees will remain: Andy Rasdal, the current Executive Chairman of the Board, who effective as of the close of business on the date of this quarterly report will reassume the role of CEO, and Nooshin Hussainy, who will remain Chief Financial Officer. During this time the Company also plans to continue to seek strategic alternatives that may be in the best interests of its stockholders, while it explores establishing third party coverage and reimbursement for the Obalon Balloon System. If the Company is unsuccessful in either of these two endeavors over the next several months, there is a high likelihood it may need to sell all or portions of its business, liquidate all or some of its assets or seek bankruptcy protection, any of which could result in a significant decrease in value for all stakeholders. If the Company determines to proceed with a plan to establish reimbursement coverage for its products, it will need additional capital to fund operations beyond the end of 2020 and there is no assurance that such capital will be available on acceptable terms or at all.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (Nasdaq: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit http://www.obalon.com.
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, periodic report on Form 10-Q for the period ended March 31, 2020 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except shares and per share data)
|Three Months Ended
|Cost of revenue||541||1,232|
|Research and development||1,257||2,439|
|Selling, general and administrative||3,893||6,204|
|Total operating expenses||5,150||8,643|
|Loss from operations||(4,911||)||(8,100||)|
|Interest income (expense), net||35||(190||)|
|Other expense, net||(385||)||—|
|Net loss and comprehensive loss||$||(5,261||)||$||(8,290||)|
|Net loss per share, basic and diluted||$||(0.68||)||$||(3.59||)|
|Weighted-average common shares outstanding, basic and diluted||7,725,205||2,311,329|
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except shares and par value data)
|March 31, 2020||December 31,
|Cash and cash equivalents||$||8,915||$||14,055|
|Accounts receivable, net||461||285|
|Other current assets||4,786||1,959|
|Total current assets||15,570||18,235|
|Property and equipment, net||2,159||1,081|
|Lease right-of-use assets||1,500||1,077|
|Liabilities and Stockholders’ Equity|
|Other current liabilities||4,607||1,524|
|Current portion of lease liabilities||690||561|
|Total current liabilities||7,188||3,977|
|Lease liabilities long-term||969||567|
|Commitments and contingencies|
|Common stock, $0.001 par value; 100,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 7,731,633 and 7,724,100 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively||8||8|
|Additional paid-in capital||188,755||188,271|
|Total stockholders’ equity||11,072||15,849|
|Total liabilities and stockholders’ equity||$||19,229||$||20,393|
OBALON THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|Three Months Ended
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Amortization of right-of-use asset||122||92|
|Accretion of investment discount, net||—||(2||)|
|Amortization of debt discount||—||22|
|Change in operating assets and liabilities:|
|Accounts receivable, net||(176||)||(959||)|
|Other current assets||(2,828||)||923|
|Lease liabilities, net||(14||)||(42||)|
|Other current liabilities||3,082||195|
|Net cash used in operating activities||(4,814||)||(9,642||)|
|Maturities of short-term investments||—||2,550|
|Purchases of property and equipment||(326||)||(19||)|
|Net cash (used in) provided by investing activities||(326||)||2,531|
|Proceeds from long-term loan||—||10,000|
|Proceeds from issuance of common stock, net of issuance costs||—||607|
|Proceeds from sale of common stock upon exercise of stock options||—||1|
|Net cash provided by financing activities||—||10,608|
|Net (decrease) increase in cash and cash equivalents||(5,140||)||3,497|
|Cash and cash equivalents at beginning of period||14,055||21,187|
|Cash and cash equivalents at end of period||$||8,915||$||24,684|
|Supplemental cash flow information:|
|Unpaid issuance costs||$||—||$||26|
|Property and equipment in accounts payable||$||—||$||4|
For Obalon Therapeutics, Inc.
President and Chief Executive Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103